Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$172.78
+0.6%
$198.85
$153.58
$218.66
$305.64B0.556.00 million shs8.47 million shs
ONEOK, Inc. stock logo
OKE
ONEOK
$86.19
+1.6%
$93.64
$75.48
$118.07
$53.84B1.23.16 million shs2.76 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+0.70%-0.59%-19.19%+0.75%+5.20%
ONEOK, Inc. stock logo
OKE
ONEOK
+1.58%+6.35%-12.00%-20.98%+10.96%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.9015 of 5 stars
3.45.04.23.93.92.51.3
ONEOK, Inc. stock logo
OKE
ONEOK
4.5824 of 5 stars
3.33.02.50.93.51.73.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.85
Moderate Buy$210.7121.96% Upside
ONEOK, Inc. stock logo
OKE
ONEOK
2.64
Moderate Buy$106.4223.46% Upside

Current Analyst Ratings Breakdown

Latest OKE and ABBV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/17/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$214.00 ➝ $214.00
4/11/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/9/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$239.00 ➝ $241.00
4/8/2025
AbbVie Inc. stock logo
ABBV
AbbVie
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Neutral$194.00
3/25/2025
ONEOK, Inc. stock logo
OKE
ONEOK
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$111.00 ➝ $133.00
3/17/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/7/2025
ONEOK, Inc. stock logo
OKE
ONEOK
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$105.00 ➝ $101.00
3/6/2025
ONEOK, Inc. stock logo
OKE
ONEOK
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$109.00 ➝ $102.00
3/5/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$210.00 ➝ $240.00
3/4/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$200.00 ➝ $223.00
2/28/2025
ONEOK, Inc. stock logo
OKE
ONEOK
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$110.00
(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$56.33B5.43$12.77 per share13.53$1.90 per share90.93
ONEOK, Inc. stock logo
OKE
ONEOK
$21.70B2.48$5.14 per share16.77$28.30 per share3.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.28B$2.4071.9912.361.627.59%296.28%12.65%4/25/2025 (Estimated)
ONEOK, Inc. stock logo
OKE
ONEOK
$2.66B$5.1718.0314.493.7714.05%16.84%6.08%4/29/2025 (Estimated)

Latest OKE and ABBV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/29/2025Q1 2025
ONEOK, Inc. stock logo
OKE
ONEOK
$1.28N/AN/AN/A$8.23 billionN/A
4/25/2025Q1 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$2.51N/AN/AN/A$12.91 billionN/A
2/24/2025Q4 2024
ONEOK, Inc. stock logo
OKE
ONEOK
$1.46$1.57+$0.11$1.57$6.18 billion$7.00 billion
1/31/2025Q4 2024
AbbVie Inc. stock logo
ABBV
AbbVie
$2.98$2.16-$0.82-$0.02$14.81 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.563.80%+6.04%273.33%53 Years
ONEOK, Inc. stock logo
OKE
ONEOK
$4.124.78%+1.92%79.69%N/A

Latest OKE and ABBV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/13/2025
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.643.4%4/15/20254/15/20255/15/2025
1/22/2025
ONEOK, Inc. stock logo
OKE
ONEOK
quarterly$1.033.88%2/3/20252/3/20252/14/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
17.94
0.66
0.55
ONEOK, Inc. stock logo
OKE
ONEOK
1.59
0.81
0.59

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
ONEOK, Inc. stock logo
OKE
ONEOK
69.13%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
ONEOK, Inc. stock logo
OKE
ONEOK
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.76 billionOptionable
ONEOK, Inc. stock logo
OKE
ONEOK
2,970624.62 million583.02 millionOptionable

Recent News About These Companies

ONEOK, Inc. stock logo
Gabelli Funds LLC Cuts Position in ONEOK, Inc. (NYSE:OKE)
ONEOK, Inc. stock logo
ONEOK, Inc. (NYSE:OKE) Position Raised by XTX Topco Ltd
ONEOK, Inc. stock logo
ONEOK, Inc. (NYSE:OKE) Shares Sold by Cohen & Steers Inc.
ONEOK, Inc. stock logo
Fmr LLC Acquires 53,365 Shares of ONEOK, Inc. (NYSE:OKE)
Oneok (OKE) Gets a Buy from J.P. Morgan
ONEOK, Inc. stock logo
9,089 Shares in ONEOK, Inc. (NYSE:OKE) Bought by FIL Ltd

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$172.78 +1.10 (+0.64%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$173.96 +1.18 (+0.68%)
As of 04/17/2025 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

ONEOK stock logo

ONEOK NYSE:OKE

$86.19 +1.39 (+1.64%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$86.26 +0.07 (+0.08%)
As of 04/17/2025 06:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ONEOK, Inc. engages in gathering, processing, fractionation, storage, transportation, and marketing of natural gas and natural gas liquids (NGL) in the United States. It operates through four segments: Natural Gas Gathering and Processing, Natural Gas Liquids, Natural Gas Pipelines, and Refined Products and Crude. The company owns natural gas gathering pipelines and processing plants in the Mid-Continent and Rocky Mountain regions; and provides midstream services to producers of NGLs. It also owns NGL gathering and distribution pipelines in Oklahoma, Kansas, Texas, New Mexico, Montana, North Dakota, Wyoming, and Colorado; terminal and storage facilities in Kansas, Nebraska, Iowa, and Illinois; NGL distribution pipelines in Kansas, Nebraska, Iowa, Illinois, and Indiana; transports refined petroleum products, including unleaded gasoline and diesel; and owns and operates truck- and rail-loading, and -unloading facilities connected to NGL fractionation, storage, and pipeline assets. In addition, the company transports and stores natural gas through regulated interstate and intrastate natural gas transmission pipelines, and natural gas storage facilities. Further, it owns and operates a parking garage in downtown Tulsa, Oklahoma; and leases excess office space and rail cars. Additionally, the company transports, stores, and distributes refined products, NGLs, and crude oil, as well as conducts commodity-related activities, including liquids blending and marketing activities. It serves integrated and independent exploration and production companies; other NGL and natural gas gathering and processing companies; crude oil and natural gas production companies; utilities; industrial companies; natural gasoline distributors; propane distributors; municipalities; ethanol producers; petrochemical, refining, and marketing companies; and heating fuel users, refineries, and exporters. ONEOK, Inc. was founded in 1906 and is headquartered in Tulsa, Oklahoma.